// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

14,170
Stories Indexed
Live
Feed Status
6
Data Sources
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
FDA · 14,170 results Live
FDA Paratek Oct 2 — 0.00

FDA Approves NUZYRA — Paratek Pharmaceuticals, Inc.

On October 2, 2018, Paratek Pharmaceuticals received FDA approval for NUZYRA (omadacycline), an oral antibiotic poised to address treatment gaps caused by the rising threat of drug…

FDA Teva Sep 14 — 0.00

FDA Approves AJOVY — Teva Pharmaceuticals USA, Inc.

Teva Pharmaceuticals USA, Inc. announced FDA approval for Fremanezumab subcutaneously, a move poised to intensify competitive pricing in the migraine market and expand the company’…

FDA Breckenridge Sep 14 — 0.00

FDA Approves EPLERENONE — Breckenridge Pharmaceutical, Inc.

Breckenridge Pharmaceuticals has secured FDA approval for ANDA 208283 regarding oral eplerenone, introducing an additional generic option that is expected to heighten market compet…

FDA BIOCODEX, Aug 20 — 0.00

FDA Approves DIACOMIT — BIOCODEX, INC.

BioCodex's FDA approval of oral Diacomit allows the manufacturer to enter the epilepsy market with its stiripentol-based treatment, potentially driving new revenue streams and disr…

FDA BIOCODEX, Aug 20 — 0.00

FDA Approves DIACOMIT — BIOCODEX, INC.

BioCodex, Inc. secured FDA clearance for Diacomit to treat refractory pediatric epileptic encephalopathies, allowing the company to capitalize on the specialized neurology market. …

FDA Pioneer Aug 13 — 0.00

FDA Approves FEXOFENADINE HYDROCHLORIDE — Pioneer Life Sciences, LLC

# FDA Approves Generic Fexofenadine Hydrochloride for Pioneer Life Sciences Pioneer Life Sciences, LLC received FDA approval for its generic fexofenadine hydrochloride oral formul…

FDA Kyowa Aug 8 — 0.00

FDA Approves POTELIGEO — Kyowa Kirin, Inc.

# FDA Approves Kyowa Kirin's POTELIGEO for Cutaneous T-Cell Lymphoma Treatment The FDA has approved Kyowa Kirin, Inc.'s POTELIGEO (mogamulizumab-kpkc), an intravenous monoclonal a…

FDA Vertex Aug 7 — 0.00

FDA Approves ORKAMBI — Vertex Pharmaceuticals Incorporated

# FDA Approves Vertex Pharmaceuticals' ORKAMBI for Cystic Fibrosis Treatment Vertex Pharmaceuticals Incorporated announced FDA approval of ORKAMBI (lumacaftor and ivacaftor) on Au…

FDA Indivior Jul 27 — 0.00

FDA Approves PERSERIS — Indivior Inc.

FDA approval of Indivior Inc.'s PERSERIS, a risperidone implant, expands the company's market footprint within the long-acting antipsychotic sector, introducing a strategic alterna…

FDA Sagent Jul 20 — 0.00

FDA Approves GEMCITABINE — Sagent Pharmaceuticals

# FDA Approves Sagent Pharmaceuticals' Generic Gemcitabine Injection Sagent Pharmaceuticals has received FDA approval for its generic gemcitabine hydrochloride intravenous formula…

FDA Accord Jul 11 — 0.00

FDA Approves DALFAMPRIDINE — Accord Healthcare Inc.

# FDA Approves Generic Dalfampridine from Accord Healthcare Accord Healthcare Inc. received FDA approval for the generic version of dalfampridine, an oral treatment for multiple s…

FDA Jazz Jun 25 — 0.00

FDA Approves EPIDIOLEX — Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc. secured a significant market foothold following the FDA approval of oral cannabidiol drug Epidiolex, positioning the biotech giant to generate substantia…

FDA Upsher-Smith Jun 21 — 0.00

FDA Approves VIGADRONE — Upsher-Smith Laboratories, LLC

Upsher-Smith Laboratories secured FDA approval for its generic Vigabatrin (VIGADRONE) oral formulation on June 21, 2018, via ANDA 210196 to capitalize on a growing market of cost-c…

FDA Slate Jun 14 — 0.00

FDA Approves BUPROPION HYDROCHLORIDE XL — Slate Run Pharmaceuticals, LLC

# FDA Approves Slate Run Pharmaceuticals' Generic Bupropion HCl XL Slate Run Pharmaceuticals, LLC has received FDA approval for its generic formulation of bupropion hydrochloride …

FDA Dr.Reddys Jun 14 — 0.00

FDA Approves BUPRENORPHINE AND NALOXONE — Dr.Reddys Laboratories Inc

Dr. Reddy’s Laboratories Inc. announced the FDA approval of its buccal Buprenorphine and Naloxone tablets, expanding its portfolio in the opioid dependence market with a potentiall…

FDA Eli May 31 — 0.00

FDA Approves OLUMIANT — Eli Lilly and Company

Eli Lilly and Company’s FDA approval of the oral rheumatoid arthritis medication OLUMIANT (baricitinib) is expected to bolster the company’s market share in the competitive JAK inh…

FDA SpecGx Apr 30 — 0.00

FDA Approves OXYCODONE HYDROCHLORIDE — SpecGx LLC

SpecGx LLC announced FDA approval for its abuse-deterrent oxycodone hydrochloride tablets, positioning the company to compete for a slice of the generic opioid market share.

FDA Zydus Apr 23 — 0.00

FDA Approves METHYLPREDNISOLONE — Zydus Lifesciences Limited

# FDA Approves Generic Methylprednisolone Oral Formulation from Zydus Lifesciences Zydus Lifesciences Limited has received FDA approval for its generic methylprednisolone oral for…

FDA Kyowa Apr 17 — 0.00

FDA Approves CRYSVITA — Kyowa Kirin, Inc.

# FDA Approves Kyowa Kirin's CRYSVITA for X-Linked Hypophosphatemia Treatment Kyowa Kirin, Inc. received FDA approval for CRYSVITA (burosumab), a first-in-class subcutaneous thera…

FDA ANI Apr 17 — 0.00

FDA Approves Unknown Drug — ANI PHARMS

ANI PHARMS secured an FDA approval for ANDA 205509, signaling a key entry into the market with commercial potential expected to bolster the company's revenue streams in the generic…